Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.60 |
| ▸ | CCR1 | P32246 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22209466 | 1.00 | ELANE (0.60) | ELANECCR1KCNH2CYP2C9CYP2C19 | |
| SCHEMBL18586364 | 0.90 | ELANE (0.61) | ELANECCR1EPHX2MEN1KMT2A | |
| SCHEMBL20484667 | 0.90 | ELANE (0.61) | ELANECCR1EPHX2MEN1KMT2A | |
| SCHEMBL18620688 | 0.89 | ELANE (0.58) | ELANECCR1KCNH2 | |
| SCHEMBL22209518 | 0.89 | ELANE (0.58) | ELANECCR1KCNH2 | |
| SCHEMBL22209487 | 0.88 | ELANE (0.51) | ELANECCR1CYP2C9CYP2C19EPHX2 | |
| SCHEMBL18621641 | 0.88 | ELANE (0.51) | ELANECCR1CYP2C9CYP2C19EPHX2 | |
| SCHEMBL18621630 | 0.85 | TAS1R3 (0.50) | ELANECCR1CYP2C9CYP2C19XIAP | |
| SCHEMBL22209536 | 0.85 | TAS1R3 (0.50) | ELANECCR1CYP2C9CYP2C19XIAP | |
| SCHEMBL22209426 | 0.84 | ACE (0.57) | ELANECCR1KCNH2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10711036-B2 | MALT1 inhibitors and uses thereof | CORNELL UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
| WO-2017040304-A1 | MALT1 INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711036-B2 | MALT1 inhibitors and uses thereof | MALT1, BCL3, BCL6 | ELANE 2951/4885CCR1 1717/4885KCNH2 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.